Erythropoietin: a novel treatment for traumatic optic neuropathy—a pilot study

Kashkouli, Mohsen Bahmani; Pakdel, Farzad; Sanjari, Mostafa Soltan; Haghighi, Anousheh; Nojomi, Marzieh; Homaee, Mohammad Hossein; Heirati, Abtin

doi:10.1007/s00417-010-1534-3

Cited by 53 publications

(48 citation statements)

References 32 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…81 Erythropoietin In a study comparing intravitreal erythropoietin (EPO) and conservative management for patients with indirect TON, patients treated with EPO showed a greater improvement in best corrected visual acuity (BCVA). 82 This was supported by studies showing the neuroprotective and neuroregenerative effects of EPO in axotomized rats. 83 …”

Section: Crystallinmentioning

confidence: 85%

Traumatic Optic Neuropathy: A Review

Kumaran

Sundar

Chye

2015

Craniomaxillofacial Trauma & Reconstruction

View full text Add to dashboard Cite

The aim of this article is to evaluate current literature on investigation and management of traumatic optic neuropathy (TON), propose recommendations for diagnosis and management, and explore novel future treatments. TON, though uncommon, causes substantial visual loss. Without clear guidelines, there is much ambiguity regarding its diagnosis and management. Investigation and treatment (conservative, medical, surgical, and combined) vary widely between centers. Electronic databases PubMed, MEDLINE, PROSPERO, CENTRAL, and EMBASE were searched for content that matched "Traumatic optic neuropathy." Articles with abstracts and full text available, published in the past 10 years, written English and limited to human adults, were selected. All study designs were acceptable except case reports and case series with fewer 10 patients. All abstracts were then evaluated for relevance. References of these studies were evaluated and if also relevant, included. A total of 2,686 articles were retrieved and 43 examined for relevance. Of these, 23 articles were included. TON is a clinical diagnosis. Visual-evoked potential is useful in diagnosis and prognosis. Computed tomography demonstrates canal fractures and concomitant injuries. Magnetic resonance images should be reserved for select and stable patients. Conservative treatment is appropriate in mild TON. Steroids are of questionable benefit and may be harmful. Surgery should be reserved for patients with radiological evidence of compression and individualized.

show abstract

Section: Crystallinmentioning

confidence: 85%

Traumatic Optic Neuropathy: A Review

Kumaran

Sundar

Chye

2015

Craniomaxillofacial Trauma & Reconstruction

View full text Add to dashboard Cite

show abstract

“…61 Seven patients with indirect traumatic optic neuropathy were given 10 000 units per day of recombinant EPO for 3 days and compared with placebo. The patients showed significant clinical improvement.…”

Section: Current Clinical Trialsmentioning

confidence: 99%

Revisiting the role of erythropoietin for treatment of ocular disorders

Ding

Leow

Munisvaradass

et al. 2016

Eye

View full text Add to dashboard Cite

Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.

show abstract

“…[19][20][21] Furthermore, EPO was reported to protect optic nerve in patients with traumatic optic neuropathy, clinically. 25 They found visual acuity increase in these patients after the systemic EPO application. This finding made us wonder whether it can protect ON in patients with CRF undergoing PD.…”

Section: Discussionmentioning

confidence: 97%